Expertise in
10
conditions

Dr. Mark R. Hutchins

Oncology
Nebraska Hematology-Oncology PC
4004 Pioneer Woods Dr, 
Lincoln, NE 
Accepting New Patients
Expertise in
10
conditions
Nebraska Hematology-Oncology PC
4004 Pioneer Woods Dr, 
Lincoln, NE 

Overview

Mark Hutchins is an Oncologist practicing medicine in Lincoln, Nebraska.

Dr. Hutchins is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Multiple Myeloma, Inflammatory Breast Cancer, Lung Cancer, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 4 clinical trials. Dr. Hutchins is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NE

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Nebraska Hematology-Oncology PC
4004 Pioneer Woods Dr, Lincoln, NE 68506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Veliparib, Carboplatin
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 3 Less Clinical Trials

1 Total Publications

Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
Journal: Anticancer research
Published: September 04, 2016
Similar Doctors
Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center

505 S 45th St, 
Omaha, NE 
 (47.3 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicole Shonka is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Shonka is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Shonka is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

The Urology Cancer Center

17607 Gold Plz, 
Omaha, NE 
 (39.1 miles away)
402-991-8468
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luke Nordquist is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Nordquist is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Prostatectomy. Dr. Nordquist is currently accepting new patients.

Expertise in
89
conditions
Expertise in
89
conditions
Referral may be required

Bryan Medical Center Imaging/Radiology

4101 Tiger Lily Rd, 
Lincoln, NE 
 (2.8 miles away)
402-420-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Wallace Peterson is an Oncologist practicing medicine in Lincoln, Nebraska. Dr. Peterson is highly rated in 89 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Colorectal Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Peterson is currently accepting new patients.

Frequently Asked Questions about Dr. Mark R. Hutchins

How do I make an appointment with Dr. Mark R. Hutchins?

You can book an appointment with Dr. Mark R. Hutchins by calling their office at 402-484-4900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark R. Hutchins a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark R. Hutchins is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark R. Hutchins specialize in?

While Dr. Mark R. Hutchins is a Oncology, they have specific expertise in Paget Disease of the Breast, Multiple Myeloma, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mark R. Hutchins participate in research or clinical trials?

Yes. Dr. Mark R. Hutchins has published 1 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Mark R. Hutchins's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark R. Hutchins accept my insurance?

Dr. Mark R. Hutchins accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 402-484-4900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hutchins's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile